Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Oligonucleotides
|
April 28, 2007
Self-assembling supramolecular complexes by single-stranded extension from plasmid DNA
Mathias G Svahn, Maroof Hasan, Valeria Sigot, et al.
Biomolecular Engineering
|
September 8, 2005
Increased stability and specificity through combined hybridization of peptide nucleic acid (PNA) and locked nucleic acid (LNA) to supercoiled plasmids for PNA-anchored "Bioplex" formation
Karin E Lundin, Maroof Hasan, Pedro M Moreno, et al.
Nature Immunology
|
November 20, 2012
Trex1 regulates lysosomal biogenesis and interferon-independent activation of antiviral genes
Maroof Hasan, James Koch, Dinesh Rakheja, et al.
Immunity
|
September 1, 2015
Cytosolic Nuclease TREX1 Regulates Oligosaccharyltransferase Activity Independent of Nuclease Activity to Suppress Immune Activation
Maroof Hasan, Charles S Fermaintt, Ningguo Gao, et al.
Leukemia Research
|
April 2, 2024
Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML
Alberto Risueño, Wendy L See, Iryna Bluemmert, et al.
Cell Reports
|
November 10, 2021
TNF leads to mtDNA release and cGAS/STING-dependent interferon responses that support inflammatory arthritis
Joschka Willemsen, Marie-Therese Neuhoff, Thomas Hoyler, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
July 22, 2010
Enhanced induction of HIV-specific cytotoxic T lymphocytes by dendritic cell-targeted delivery of SOCS-1 siRNA
Sandesh Subramanya, Myriam Armant, Janelle R Salkowitz, et al.
The Lancet. Oncology
|
October 21, 2021
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
Courtney D DiNardo, Andre C Schuh, Eytan M Stein, et al.
Blood
|
June 17, 2022
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
Stéphane de Botton, Pau Montesinos, Andre C Schuh, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Oligonucleotides
|
April 28, 2007
Self-assembling supramolecular complexes by single-stranded extension from plasmid DNA
Mathias G Svahn, Maroof Hasan, Valeria Sigot, et al.
Biomolecular Engineering
|
September 8, 2005
Increased stability and specificity through combined hybridization of peptide nucleic acid (PNA) and locked nucleic acid (LNA) to supercoiled plasmids for PNA-anchored "Bioplex" formation
Karin E Lundin, Maroof Hasan, Pedro M Moreno, et al.
Nature Immunology
|
November 20, 2012
Trex1 regulates lysosomal biogenesis and interferon-independent activation of antiviral genes
Maroof Hasan, James Koch, Dinesh Rakheja, et al.
Immunity
|
September 1, 2015
Cytosolic Nuclease TREX1 Regulates Oligosaccharyltransferase Activity Independent of Nuclease Activity to Suppress Immune Activation
Maroof Hasan, Charles S Fermaintt, Ningguo Gao, et al.
Leukemia Research
|
April 2, 2024
Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML
Alberto Risueño, Wendy L See, Iryna Bluemmert, et al.
Cell Reports
|
November 10, 2021
TNF leads to mtDNA release and cGAS/STING-dependent interferon responses that support inflammatory arthritis
Joschka Willemsen, Marie-Therese Neuhoff, Thomas Hoyler, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
July 22, 2010
Enhanced induction of HIV-specific cytotoxic T lymphocytes by dendritic cell-targeted delivery of SOCS-1 siRNA
Sandesh Subramanya, Myriam Armant, Janelle R Salkowitz, et al.
The Lancet. Oncology
|
October 21, 2021
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
Courtney D DiNardo, Andre C Schuh, Eytan M Stein, et al.
Blood
|
June 17, 2022
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
Stéphane de Botton, Pau Montesinos, Andre C Schuh, et al.
Page
of 2